Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

Seven out of 67 children who were given bluebird's (BLUE) gene therapy Skysona during clinical trials ended up developing ...

Newly released data reveals that seven out of 67 children treated with Bluebird Bio Inc's (NASDAQ:BLUE) gene therapy for a ...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood ...

The recent publication in the New England Journal of Medicine highlighting an increased incidence of hematologic cancers in patients treated with Bluebird Bio’s Skysona product has raised concerns.

Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood ...

While the use of elivaldogene autotemcel (eli-cel; Skysona) gene therapy has demonstrated long-term efficacy in patients with ...

(BLUE) plans to reduce workforce by 25%, optimize cost structure, focus on commercial launches, and aim for cash flow ...

(RTTNews) - bluebird bio (BLUE) announced it is implementing a restructuring intended to optimize cost structure and enable quarterly cash flow ...